Sep 7, 2026
12:30 PM2:00 PM
ePoster presentations
ePoster Stage 4: Techniques to assess nutritional status
Cristian Cobilinschi
PP379
MORPHOFUNCTIONAL PHENOTYPE CLUSTER AND MORTALITY IN HOSPITALIZED PATIENTS: RESULTS FROM THE DRECO STUDY
M. García Olivares1,*, Y. GARCIA DELGADO2, M. GONZALO MARIN3, J. M. GUARDIA BAENA4, A. M. SANCHEZ BAO5, I. PRIOR SANCHEZ6, M. CIVERA ANDRES7, D. DE LUIS ROMAN8, G. OLVEIRA3, J. M. GARCIA ALMEIDA1, D. BELLIDO GUERRERO5 on behalf of DRECO STUDY
1ENDOCRINOLOGY AND NUTRITION, VIRGEN DE LA VICTORIA HOSPITAL, MALAGA, 2ENDOCRINOLOGY AND NUTRITION, INSULAR MATERNO INFLANTIL HOSPITAL, CANARIAS, 3ENDOCRINOLOGY AND NUTRITION, REGIONAL UNIVERSITY HOSPITAL, MALAGA, 4ENDOCRINOLOGY AND NUTRITION, VIRGEN DE LAS NIEVES HOSPITAL, GRANADA, 5ENDOCRINOLOGY AND NUTRITION, FERROL HOSPITAL, GALICIA, 6ENDOCRINOLOGY AND NUTRITION, JAEN UNIVERSITY HOSPITAL, JAEN, 7ENDOCRINOLOGY AND NUTRITION, UNIVERSITY CLINICAL HOSPITAL VALENCIA, VALENCIA, 8ENDOCRINOLOGY AND NUTRITION, UNIVERSITY CLINICAL HOSPITAL OF VALLADOLID, VALLADOLID, Spain
Rationale: Early identification of patients at high nutritional and functional risk is essential to improve clinical outcomes. Morphofunctional assessment integrates body composition and functional parameters, potentially enhancing prognostic stratification.
Methods: Multicenter observational study including hospitalized patients. Morphofunctional variables were assessed: rectus femoris cross-sectional area (RFCSA) by ultrasound, phase angle (PhA) by bioelectrical impedance analysis, and handgrip strength. A hierarchical cluster analysis identified patient groups. Differences were analyzed using Student’s t-test. Mortality at 6 months was evaluated using Cox regression and Kaplan–Meier curves.
Results: Two clusters were identified: Group 1 (n=533, 71.5%) and Group 2 (n=212, 28.5%). Group 2 showed higher RFCSA (4.84 vs 3.09 cm²), handgrip strength (36.9 vs 23.5 kg), and PhA (6.01 vs 4.46°) (p<0.001 for all). Overall mortality was 13.4%, lower in Group 2 (8.5% vs 15.4%, p=0.013). Cox analysis showed reduced mortality risk in Group 2 (HR 0.53; 95% CI 0.32–0.88; p=0.014). Six-month survival was higher in Group 2 (92.9% vs 87.2%).
Image:
Conclusion: Cluster analysis identifies distinct morphofunctional phenotypes with different prognoses. Preserved morphofunctional status is associated with lower mortality. These findings support the integration of morphofunctional assessment into routine clinical practice for risk stratification.
Disclosure of Interest: None declared